Drugmaker AstraZeneca will cap out-of-pocket costs at $35 for all its inhaler products, the company announced Monday. The cap is effective June 1, and will apply to the company’s entire range of inhaler products used to treat asthma and chronic obstructive pulmonary disease (COPD), including inhalers like Symbicort, Breztri Aerosphere and Airsupra. The cap will be applicable for patients who are uninsured or underinsured. The announcement follows a similar move by rival company Boehringer Ingelheim and comes amid scrutiny from Democratic lawmakers over the cost of inhalers. The companies are also facing scrutiny from federal regulators for anticompetitive practices that can d
Hence then, the article about astrazeneca follows rival will cap inhaler prices at 35 per month amid scrutiny was published today ( ) and is available onThe Hill ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( AstraZeneca follows rival, will cap inhaler prices at $35 per month amid scrutiny )